早期非小细胞肺癌精确免疫治疗路线图

IF 29.7 1区医学 Q1 ONCOLOGY

Cancer discovery Pub Date : 2025-05-02 DOI:10.1158/2159-8290.CD-25-0262

Alessandra Vaccaro, Zahraa Rahal, Humam Kadara, Tina Cascone

引用次数: 0

摘要

免疫疗法已经彻底改变了早期非小细胞肺癌的治疗；然而，许多患者未能获得长期的益处，部分原因是生物标志物预测不完整或不一致。综合多组学，结合肿瘤内在、免疫微环境和全身因素，为精确免疫治疗提供了更全面的框架，使患者分层、治疗选择和结果得到改善。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

A Roadmap to Precision Immunotherapy for Early-Stage Non-Small Cell Lung Cancer.

Immunotherapy has revolutionized the treatment of early-stage non-small cell lung cancer; yet many patients fail to achieve long-lasting benefit, partially because of incomplete or inconsistent biomarker predictions. Integrative multiomics, combining tumor-intrinsic, immune microenvironment, and systemic factors, offer a more comprehensive framework for precision immunotherapy, enabling improved patient stratification, treatment selection and outcomes.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Cancer discovery ONCOLOGY-

CiteScore

22.90

自引率

1.40%

发文量

838

审稿时长

6-12 weeks

期刊介绍： Cancer Discovery publishes high-impact, peer-reviewed articles detailing significant advances in both research and clinical trials. Serving as a premier cancer information resource, the journal also features Review Articles, Perspectives, Commentaries, News stories, and Research Watch summaries to keep readers abreast of the latest findings in the field. Covering a wide range of topics, from laboratory research to clinical trials and epidemiologic studies, Cancer Discovery spans the entire spectrum of cancer research and medicine.